The Hague, Aug 30 (EFE).- The European Medicines Agency (EMA) recommended this Wednesday to approve the vaccine adapted by the pharmaceutical company Pfizer against the Omicron XBB.1.5 subvariant and intended for adults and children from six months of age. age.
The European agency’s committee for human medicines (CHMP) concluded that all available data on Comirnaty (Pfizer’s trade name of the dose), and all other adapted vaccines, including information on safety, efficacy and immunogenicity, are sufficient to support this updated vaccine against COVID-19.
The vaccine, known as Comirnaty Omicron XBB.1.5, will be used to prevent disease caused by SARS-CoV-2 in adults and children from 6 months of age, and as this subvariant is closely related to other circulating variants currently, “the vaccine is expected to help maintain optimal protection against COVID-19 also caused by these other variants,” the EMA noted.
The EMA recalled that adults and children from 5 years of age should receive a single dose, regardless of their vaccination history against COVID-19, while children from 6 months to 4 years of age may receive one or three doses depending on if they have completed a primary vaccination course or have had COVID-19.
Patient-reported side effects are mild and short-lived, and include headache, diarrhea, joint and muscle pain, tiredness, chills, fever, and pain or swelling at the injection site.
“On rare occasions, more serious side effects may occur,” says the EMA.
The EMA will now send this recommendation to the European Commission, which has the final say on the approval of medicines backed by the European agency. EFE
ir/cat/ad
2023-08-30 14:34:33
#EMA #supports #updated #Pfizer #vaccine #omicron #subvariants
